• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌的变异:临床意义与分子机制

Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

作者信息

Zhao Shankun, Xu Youwen, Wu Weizhou, Wang Pan, Wang Yichao, Jiang Hao, Zhu Jie

机构信息

Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.

Department of Clinical Laboratory, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.

出版信息

Front Oncol. 2021 Jun 25;11:693295. doi: 10.3389/fonc.2021.693295. eCollection 2021.

DOI:10.3389/fonc.2021.693295
PMID:34249744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8267411/
Abstract

Cholangiocarcinoma (CCA), a high mortality malignant carcinoma characterized by advanced disease and frequent recurrence, constitutes a major challenge for treatment and prognosis. AT-rich interaction domain 1A () variation is a distinct genetic entity in CCA, getting mounting concerns recently. Here, we comprehensively reviewed the clinical significance and molecular mechanisms of alterations in CCA. Based on the independent data derived from 29 relevant studies, the variation rate of in intrahepatic and extrahepatic CCA is reported at 6.9-68.2% and 5-55%, respectively. Most of the included studies (28/29, 96.6%) suggest that serves as a tumor suppressor in CCA. variation may be an important prognostic indicator to predict disease mortality, metastasis, and recurrence in patients with CCA. Multifactorial molecular mechanisms are involved in the relationship between variations and the pathogenesis and pathophysiology of CCA, including disruption of the cell cycle, chromatin remodeling, oxidative stress damage, DNA hypermethylation, and the interaction of multiple genes being affected. This review describes that variation might be a potential diagnostic and prognostic biomarker for CCA. Future diagnoses and treatments targeting hint towards a precision medicine strategy in the management of CCA.

摘要

胆管癌(CCA)是一种死亡率高的恶性肿瘤,其特点是疾病进展晚期且频繁复发,对治疗和预后构成重大挑战。富含AT的相互作用结构域1A()变异是CCA中一种独特的遗传实体,最近受到越来越多的关注。在此,我们全面综述了CCA中改变的临床意义和分子机制。基于来自29项相关研究的独立数据,肝内和肝外CCA中的变异率分别报告为6.9 - 68.2%和5 - 55%。大多数纳入研究(28/29,96.6%)表明在CCA中作为一种肿瘤抑制因子。变异可能是预测CCA患者疾病死亡率、转移和复发的重要预后指标。多因素分子机制参与了变异与CCA发病机制和病理生理学之间的关系,包括细胞周期破坏、染色质重塑、氧化应激损伤、DNA高甲基化以及多个受影响基因的相互作用。本综述表明变异可能是CCA的一种潜在诊断和预后生物标志物。未来针对的诊断和治疗暗示了CCA管理中的精准医学策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e49/8267411/5cac88a8ee83/fonc-11-693295-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e49/8267411/69af49846eac/fonc-11-693295-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e49/8267411/21bb076ce3b7/fonc-11-693295-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e49/8267411/5cac88a8ee83/fonc-11-693295-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e49/8267411/69af49846eac/fonc-11-693295-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e49/8267411/21bb076ce3b7/fonc-11-693295-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e49/8267411/5cac88a8ee83/fonc-11-693295-g003.jpg

相似文献

1
Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.胆管癌的变异:临床意义与分子机制
Front Oncol. 2021 Jun 25;11:693295. doi: 10.3389/fonc.2021.693295. eCollection 2021.
2
Roles of ARID1A variations in colorectal cancer: a collaborative review.ARID1A 变异在结直肠癌中的作用:合作综述。
Mol Med. 2022 Apr 14;28(1):42. doi: 10.1186/s10020-022-00469-6.
3
alterations and their clinical significance in cholangiocarcinoma.胆管癌的改变及其临床意义
PeerJ. 2020 Dec 3;8:e10464. doi: 10.7717/peerj.10464. eCollection 2020.
4
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.胆管癌的突变谱分析:预后及治疗意义
PLoS One. 2014 Dec 23;9(12):e115383. doi: 10.1371/journal.pone.0115383. eCollection 2014.
5
Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.ARID1A 缺失诱导具有组蛋白乙酰化的干性基因 ALDH1A1 表达,从而导致胆管癌恶性亚型的发生。
Carcinogenesis. 2020 Jul 10;41(6):734-742. doi: 10.1093/carcin/bgz179.
6
Protein-loss of SWI/SNF-complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma.SWI/SNF复合体核心亚基的蛋白质丢失对肝内和肝外胆管癌组织学亚型的预后有影响。
Oncol Lett. 2021 May;21(5):349. doi: 10.3892/ol.2021.12610. Epub 2021 Mar 3.
7
Role and potential clinical utility of ARID1A in gastrointestinal malignancy.ARID1A 在胃肠恶性肿瘤中的作用及潜在临床应用价值。
Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108360. doi: 10.1016/j.mrrev.2020.108360. Epub 2020 Dec 4.
8
Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines.卵巢透明细胞腺癌细胞系中SWI/SNF染色质重塑/肿瘤抑制蛋白ARID1A和Brg1磷酸化水平的质谱分析
J Proteome Res. 2014 Nov 7;13(11):4959-69. doi: 10.1021/pr500470h. Epub 2014 Aug 1.
9
Molecular classification of cholangiocarcinoma.胆管癌的分子分类。
Curr Opin Gastroenterol. 2020 Mar;36(2):57-62. doi: 10.1097/MOG.0000000000000611.
10
Genomic and transcriptional alterations of cholangiocarcinoma.胆管癌的基因组和转录改变
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):380-7. doi: 10.1002/jhbp.67. Epub 2014 Feb 13.

引用本文的文献

1
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response.基于影像学测量的肝内胆管癌放疗后强化变化反映了反应的物理机制。
medRxiv. 2024 Sep 12:2024.09.11.24313334. doi: 10.1101/2024.09.11.24313334.
2
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.通过组学和多组学方法揭示肝内胆管癌的异质性
Cancers (Basel). 2024 Aug 20;16(16):2889. doi: 10.3390/cancers16162889.
3
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system.

本文引用的文献

1
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.肝内胆管癌结局的遗传决定因素。
Hepatology. 2021 Sep;74(3):1429-1444. doi: 10.1002/hep.31829.
2
Protein-loss of SWI/SNF-complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma.SWI/SNF复合体核心亚基的蛋白质丢失对肝内和肝外胆管癌组织学亚型的预后有影响。
Oncol Lett. 2021 May;21(5):349. doi: 10.3892/ol.2021.12610. Epub 2021 Mar 3.
3
Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
PBRM1基因突变可能使一种胆管癌亚型对靶向DNA损伤修复系统的药物敏感。
NPJ Precis Oncol. 2023 Jul 3;7(1):64. doi: 10.1038/s41698-023-00409-5.
4
Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective.靶向 ARID1A 缺陷型癌症:免疫代谢视角。
Cells. 2023 Mar 21;12(6):952. doi: 10.3390/cells12060952.
5
Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?胆管癌中的同源重组修复:PARP抑制的主要靶点?
Cancers (Basel). 2022 May 23;14(10):2561. doi: 10.3390/cancers14102561.
6
Roles of ARID1A variations in colorectal cancer: a collaborative review.ARID1A 变异在结直肠癌中的作用:合作综述。
Mol Med. 2022 Apr 14;28(1):42. doi: 10.1186/s10020-022-00469-6.
7
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.胆管癌中 ARID1A 和 PI3K/AKT 通路改变的治疗靶向。
PeerJ. 2022 Jan 13;10:e12750. doi: 10.7717/peerj.12750. eCollection 2022.
全面分析基因组突变特征和肿瘤突变负担对肝内胆管癌预后的影响。
BMC Cancer. 2021 Feb 3;21(1):112. doi: 10.1186/s12885-021-07788-7.
4
Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.胆管腺瘤可能是小胆管型肝内胆管癌的前驱病变。
Histopathology. 2021 Jan;78(2):310-320. doi: 10.1111/his.14222. Epub 2020 Sep 15.
5
alterations and their clinical significance in cholangiocarcinoma.胆管癌的改变及其临床意义
PeerJ. 2020 Dec 3;8:e10464. doi: 10.7717/peerj.10464. eCollection 2020.
6
Intrahepatic Cholangiocarcinoma.肝内胆管癌
Semin Intervent Radiol. 2020 Dec;37(5):475-483. doi: 10.1055/s-0040-1719188. Epub 2020 Dec 11.
7
Somatic Mutation Profiling of Intrahepatic Cholangiocarcinoma: Comparison between Primary and Metastasis Tumor Tissues.肝内胆管癌的体细胞突变谱分析:原发肿瘤组织与转移肿瘤组织的比较
J Oncol. 2020 Sep 17;2020:5675020. doi: 10.1155/2020/5675020. eCollection 2020.
8
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.晚期/转移性胆管癌全身治疗的最新进展
Cancers (Basel). 2020 Sep 11;12(9):2599. doi: 10.3390/cancers12092599.
9
What 20 years of research has taught us about the TP53 p.R337H mutation.20 年研究揭示 TP53 p.R337H 突变的奥秘。
Cancer. 2020 Nov 1;126(21):4678-4686. doi: 10.1002/cncr.33143. Epub 2020 Aug 17.
10
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies.哺乳动物 SWI/SNF 染色质重塑复合物:新兴机制和治疗策略。
Trends Genet. 2020 Dec;36(12):936-950. doi: 10.1016/j.tig.2020.07.011. Epub 2020 Aug 29.